ReviewHuman
Fighting against depression with TREK-1 blockers: Past and future. A focus on spadin
Pharmacology & therapeutics, 2019 Feb. Djillani A, Pietri M, Mazella J and 2 others.
Study type
Review
Subjects
Human participants (PubMed MeSH: Humans)
Journal
Pharmacology & therapeutics
Published
2019 Feb
PubMed
Where PepCue cites this
This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.
Indexed under
MeSH terms assigned by the National Library of Medicine.
AnimalsAntidepressive AgentsDepressionHumansPeptidesPotassium Channels, Tandem Pore Domain
Other papers on PE-22-28
Journal article · 2021
Genetic and pharmacological inhibition of two-pore domain potassium channel TREK-1 alters depression-related behaviors and neuronal plasticity in the hippocampus in mice
Journal article · 2018The Involvement of Sortilin/NTSR3 in Depression as the Progenitor of Spadin and Its Role in the Membrane Expression of TREK-1
Journal article · 2017Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity
PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.
Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page